Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Minocycline
Drug ID BADD_D01470
Description Minocycline was first described in the literacture in 1966.[A190681] It is a second generation tetracycline antibiotic that is active against gram-negative and gram-positive bacteria.[A190723] Like other semisynthetic tetracyclines, minocycline has modifications to carbons 7-9 on the D ring to generate higher efficacy than previous tetracyclines.[A190723] Minocycline was granted FDA approval on 30 June 1971.[L11695]
Indications and Usage Oral and topical minocycline are indicated to treat inflammatory lesions of acne vulgaris.[L11701,L11704,L11719] Subgingival microspheres are indicated as an adjunct treatment in the reduction of pocket depth in adults with periodontitis.[L11716] Oral and intravenous formulations are indicated to treat infections of susceptible microorganisms.[L11707,L11710,L11713] These include rickettsiae, _Mycoplasma pneumoniae_, _Chlamydia trachomatis_, _Chlamydophila psittaci_, _Chlamydia trachomatis_, _Ureaplasma urealyticum_, _Borrelia recurrentis_, _Haemophilus ducreyi_, _Yersinia pestis_, _Francisella tularensis_, _Vibrio cholerae_, _Campylobacter fetus_, _Brucella_ species, _Bartonella bacilliformis_, _Klebsiella granulomatis_, _Escherichia coli_, _Enterobacter aerogenes_, _Shigella_ species, _Acinetobacter_ species, _Haemophilus influenzae_, and _Kelbsiella_ species.[L11710]
Marketing Status approved; investigational
ATC Code A01AB23; D10AF07; J01AA08
DrugBank ID DB01017
KEGG ID D05045
MeSH ID D008911
PubChem ID 54675783
TTD Drug ID D08LTU
NDC Product Code 49884-512; 69489-212; 72356-101; 49884-513; 42291-589; 69489-201; 72356-103; 49884-511; 42291-591
UNII FYY3R43WGO
Synonyms Minocycline | Minox 50 | Aknemin | Aknin-Mino | Aknin Mino | Aknosan | Mynocine | Apo-Minocycline | Apo Minocycline | Arestin | Blemix | Cyclomin | Cyclops | Dentomycin | Dynacin | Icht-Oral | Icht Oral | Klinomycin | Lederderm | Mestacine | Minakne | Mino-Wolff | Mino Wolff | Minocin | Minocin MR | Minoclir | Minocycline Hydrochloride | Hydrochloride, Minocycline | Minocycline Monohydrochloride | Monohydrochloride, Minocycline | Minocycline, (4R-(4 alpha,4a beta,5a beta,12a beta))-Isomer | Minolis | Minomycin | Minoplus | Minotab | Akamin | Akne-Puren | Akne Puren
Chemical Information
Molecular Formula C23H27N3O7
CAS Registry Number 10118-90-8
SMILES CN(C)C1C2CC3CC4=C(C=CC(=C4C(=C3C(=O)C2(C(=C(C1=O)C(=O)N)O)O)O)O)N(C)C
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice.
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Hallucination19.10.04.003--
Hallucination, auditory19.10.04.004---
Headache17.14.01.0010.005797%
Henoch-Schonlein purpura01.01.04.001; 10.02.02.004; 23.06.01.002; 24.07.06.003---
Hepatic encephalopathy09.01.03.006; 17.13.01.0030.000118%-
Hepatic failure09.01.03.0020.000354%
Hepatic fibrosis09.01.04.002; 24.08.06.0020.000118%-
Hepatic function abnormal09.01.02.0010.001122%-
Hepatic necrosis09.01.07.0020.000295%
Hepatitis09.01.07.0040.002149%-
Hepatitis acute09.01.07.0050.000472%-
Hepatitis cholestatic09.01.01.0020.000413%-
Hepatitis chronic active09.01.07.006; 11.07.01.0020.000177%-
Hepatomegaly09.01.05.0010.000177%-
Hepatotoxicity09.01.07.009; 12.03.01.0080.000531%-
Hidradenitis23.02.03.013---
Hyperacusis04.02.02.001; 17.04.03.003---
Hyperbilirubinaemia01.06.04.003; 09.01.01.003; 14.11.01.0100.000295%-
Hypersensitivity10.01.03.0030.002538%
Hyperthyroidism05.02.02.001; 14.11.01.0110.003778%
Hypoaesthesia17.02.06.023; 23.03.03.0810.001488%-
Hypoglycaemia05.06.03.001; 14.06.03.001--
Hypothyroidism05.02.03.001; 14.11.01.0120.000767%
Hypoxia22.02.02.003--
Increased tendency to bruise01.01.03.005; 23.06.01.009; 24.07.06.0120.000118%-
Influenza like illness08.01.03.0100.001263%
Interstitial lung disease10.02.01.033; 22.01.02.0030.000413%-
Intestinal infarction07.15.02.006; 24.04.08.0080.000354%-
Intestinal ischaemia07.15.02.001; 24.04.08.0010.000177%-
Intracranial pressure increased17.07.02.0020.001358%-
The 5th Page    First    Pre   5 6 7 8 9    Next   Last    Total 14 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene